The AHA today urged the Medicare Payment Advisory Commission to withdraw its draft recommendation to reduce Part B drug payment rates to hospitals participating in the 340B Drug Pricing Program. “This recommendation is outside of the scope of MedPAC’s mission, lacks a clear purpose and penalizes certain hospitals for their ability to obtain discounts on the items and services they purchase,” wrote Ashley Thompson, AHA senior vice president for public policy analysis and development. “The AHA strongly urges MedPAC to withdraw this draft recommendation and, instead, to undertake an analysis of the trend of rapidly increasing drug prices, which presents the Medicare program and its beneficiaries with remarkable challenges.” MedPAC expects to vote on payment recommendations for fiscal year 2017 later this week.

Related News Articles

News
Reps. Peter Welch, D-Vt., Suzan DelBene, D-Wash., Darin LaHood, R-Ill., and Brad Wenstrup, R-Ohio, yesterday reintroduced the Value in Health Care Act, AHA-…
News
The Centers for Medicare & Medicaid Services today advised clinicians in the Medicare Quality Payment Program who earned but did not receive an alternative…
Headline
Congress should not extend Medicare sequestration to help pay for the bipartisan infrastructure framework because health care providers cannot sustain…
Headline
The Centers for Medicare & Medicaid Services is accepting comments through Aug. 11 on whether to establish a national Medicare coverage policy for…
Headline
The AHA and other national hospital organizations today urged Senate leadership and senators supporting a bipartisan $1.2 trillion infrastructure agreement…
Headline
The Medicare Payment Advisory Commission yesterday issued its June report to Congress on refinements to Medicare payment systems and issues affecting the…